1. Search Result
Search Result
Results for "

HPAC

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Inhibitory Antibodies

3

Natural
Products

4

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148439
    Daraxonrasib
    Maximum Cited Publications
    10 Publications Verification

    RMC-6236; RAS-IN-2

    Ras PERK Cancer
    Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
    Daraxonrasib
  • HY-N0326
    L-Methionine
    5+ Cited Publications

    Environmental Pollutants Endogenous Metabolite Apoptosis Keap1-Nrf2 Inflammation/Immunology Cancer
    L-Methionine is an L-isomer of orally active Methionine, an essential amino acid. Methionine is a strong liver antidote that acts as a liver protector. L-Methionine can inhibit cell proliferation and induce cell apoptosis. L-Methionine has antitumor and antioxidant activity .
    L-Methionine
  • HY-153723
    BI-2493
    4 Publications Verification

    Ras Cancer
    BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research .
    BI-2493
  • HY-P99237

    MMUC 1206A

    Mucin Cancer
    Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a Kd of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model .
    Sofituzumab
  • HY-N6678
    Zearalanone
    2 Publications Verification

    Drug Metabolite Metabolic Disease
    Zearalanone is a reductive metabolite of Zearalenone (HY-103447). Zearalanone binds to serum albumin across multiple species. Zearalanone enhances the binding affinity of Warfarin (HY-B0687) to serum albumin .
    Zearalanone
  • HY-N0326R

    Reference Standards Endogenous Metabolite Keap1-Nrf2 Apoptosis Inflammation/Immunology Cancer
    L-Methionine (Standard) is the analytical standard of L-Methionine. This product is intended for research and analytical applications. L-Methionine is an L-isomer of orally active Methionine, an essential amino acid. Methionine is a strong liver antidote that acts as a liver protector. L-Methionine can inhibit cell proliferation and induce cell apoptosis. L-Methionine has antitumor and antioxidant activity .
    L-Methionine (Standard)
  • HY-P991229

    AGS-1C4D4; AGS-PSCA

    Complement System Cancer
    AGS-1C4D4 is a fully human IgG1κ monoclonal antibody targeting PSCA, with a Ka value of 0.2 nM. AGS-1C4D4 mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PSCA-expressing cells. AGS-1C4D4 can be used for the research of pancreatic cancer .
    MK-4721
  • HY-158703

    Ras Cancer
    KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC50 of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity .
    KRAS G12D inhibitor 24
  • HY-163468

    Src Cancer
    SRC-3-IN-1 (compound SI-10) is a steroid receptor coactivator 3 (SRC-3) inhibitor (IC50=3.3 μM). SRC-3-IN-1 has good water solubility, oral bioavailability, and improved selectivity profile. SRC-3-IN-1 can be used in prostate cancer research .
    SRC-3-IN-1
  • HY-RS09953

    Small Interfering RNA (siRNA) Others

    PACC1 Human Pre-designed siRNA Set A contains three designed siRNAs for PACC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PACC1 Human Pre-designed siRNA Set A
    PACC1 Human Pre-designed siRNA Set A
  • HY-172210

    Epigenetic Reader Domain Apoptosis Cancer
    DDO-8958 is an orally active and selective BET BD1 inhibitor with a KD of 5.6 nM for BRD4 BD1. DDO-8958 exhibits low nanomolar inhibitory activity against all BET BD1 bromodomains except for BRDT BD1. DDO-8958 can inhibit the proliferation and migration, induce apoptosis and cell cycle arrest of tumor cells. DDO-8958 has anti-tumor activity .
    DDO-8958
  • HY-158076

    IAP Cancer
    S2/IAPinh is a conjugate, which consist of an inhibitor for the apoptosis protein inhibitor (IAPinh) and a ligand for sigma 2 SW43. S2/IAPinh exhibits an anti-proliferative and apoptotic-inducing effect through degradation of the cellular inhibitor for apoptosis protein (clAP-1) .
    S2/IAPinh
  • HY-180885S

    Ras ERK Cancer
    KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer .
    KRAS G12D-IN-35
  • HY-181561

    RAD51 Cancer
    BRCA2-RAD51-IN-3 is a RAD51-BRCA2 protein-protein interaction inhibitor with an EC50 of 29.35 μM and a Kd of 75.14 μM. BRCA2-RAD51-IN-3 blocks RAD51-BRCA2 binding, impairs homologous recombination in cancer cells, and induces synthetic lethality. BRCA2-RAD51-IN-3 acts in human pancreatic cancer cells and shows no activity in normal pancreatic cells. BRCA2-RAD51-IN-3 can be used for the research of pancreatic cancer .
    BRCA2-RAD51-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: